1. Home
  2. NECB vs EDIT Comparison

NECB vs EDIT Comparison

Compare NECB & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NorthEast Community Bancorp Inc.

NECB

NorthEast Community Bancorp Inc.

HOLD

Current Price

$21.93

Market Cap

282.4M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.43

Market Cap

233.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NECB
EDIT
Founded
1934
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.4M
233.3M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
NECB
EDIT
Price
$21.93
$2.43
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$4.13
AVG Volume (30 Days)
45.1K
1.7M
Earning Date
10-23-2025
11-10-2025
Dividend Yield
4.56%
N/A
EPS Growth
N/A
N/A
EPS
3.21
N/A
Revenue
$102,569,000.00
$46,383,000.00
Revenue This Year
$1.90
N/A
Revenue Next Year
$6.93
N/A
P/E Ratio
$6.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.27
$0.91
52 Week High
$29.74
$4.54

Technical Indicators

Market Signals
Indicator
NECB
EDIT
Relative Strength Index (RSI) 63.88 42.37
Support Level $21.00 $2.09
Resistance Level $22.19 $2.55
Average True Range (ATR) 0.53 0.17
MACD 0.20 0.02
Stochastic Oscillator 86.43 51.56

Price Performance

Historical Comparison
NECB
EDIT

About NECB NorthEast Community Bancorp Inc.

NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: